Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.69 |
| ▸ | SLC7A5 | Q01650 | 8/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | XIAP | P98170 | 1/20 | 0.65 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.60 |
| ▸ | NOS3 | P29474 | 3/20 | 0.59 |
| ▸ | NOS1 | P29475 | 3/20 | 0.59 |
| ▸ | NOS2 | P35228 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| M-Fluorophenylalanine SCHEMBL42948 | 1.00 | SLC1A1 (0.69) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL42949 | 1.00 | SLC1A1 (0.69) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL29424682 | 1.00 | SLC1A1 (0.69) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL29580111 | 1.00 | SLC1A1 (0.69) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL27547062 | 0.98 | SLC1A1 (0.68) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL21057063 | 0.98 | SLC1A1 (0.68) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL21057062 | 0.98 | SLC1A1 (0.68) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL31369781 | 0.91 | GRIA2 (0.71) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL366761 | 0.89 | PTPN1 (0.57) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL2314258 | 0.87 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120192379-A | Marine cyclic peptide and synthesis method and application thereof | 内蒙古大学 | 2025-06-24 | — | — | CN | claimed |
| EP-4100064-A1 | TARGETED PLASMA PROTEIN DEGRADATION | Novartis AG (CH) | 2022-12-14 | — | — | EP | claimed |
| CN-115335081-A | Targeted plasma protein degradation | 诺华股份有限公司 | 2022-11-11 | — | — | CN | claimed |
| WO-2021156792-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2021-08-12 | — | — | WO | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| US-20160022636-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | claimed |
| EP-2968240-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | claimed |
| US-20140336216-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2014152917-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | TRANSFERT PLUS LP (CA) | 2026-03-26 | — | — | US | disclosed |
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | NATIONAL HEALTH RES INST (TW) | 2026-02-19 | — | — | US | disclosed |
| EP-4673162-A1 | PATHOGEN-SPECIFIC PEPTIDE TO BLOCK VIRULENCE-RELATED SIGNALING IN CANDIDA ALBICANS | I3S - Instituto de Investigação e Inovação em Saúde, Associação (PT) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| EP-1392317-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6514965-B1 | For treating bacterial infections | ANTEX PHARMA INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2002100327-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1229913-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001035964-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | OPRK1, OPRD1, OPRM1 | SLC1A1 830/4885SLC7A5 2400/4885PTGS1 405/4885 |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | SLC1A1 2314/4885SLC7A5 1600/4885PTGS1 109/4885 |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | VSIG8, MICA, CD74 | SLC1A1 2819/4885SLC7A5 1741/4885PTGS1 3808/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | SLC1A1 1994/4885SLC7A5 3352/4885PTGS1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.